FDA Approves BMS and J&J HIV Treatments
Bristol-Myers Squibb and Johnson & Johnson announced FDA-approval of Evotaz and Prezcobix, combination HIV-1 infection treatments.
On Jan. 29, 2015, Bristol-Myers Squibb (BMS) and Johnson & Johnson (J&J) both announced FDA approval of HIV treatments. BMS announced the approval of Evotaz (atazanavir and cobicistat) when combined with other antiretroviral agents for the treatment of the HIV-1 in adults. On the same day, J&J announced the approval of Prezcobix (darunavir and cobicistat) tablets when combined with other antiretroviral agents.
Both treatments are a once-daily tablet containing a pharmacokinetic enhancer called cobicistat produced by Gilead Sciences, however, Evotaz is combined with the protease inhibitor Reyataz (atazanavir), while Prezcobix uses the protease inhibitor darunavir. The treatments are meant for patients who have not experienced any baseline resistance to the components within the treatments.
Sources:
Bristol-Myers Squibb
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
